Advanced search
Publication Cover
Hematology Volume 24, 2019 - Issue 1
Submit an article Journal homepage
3,582
Views
6
CrossRef citations to date
0
Altmetric
Articles

Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan

Bor-Sheng KoDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanView further author information
,
Ming-Chih ChangDivision of Hematology and Oncology, Mackay Memorial Hospital, Taipei, TaiwanCorrespondence[email protected]
View further author information
,
Tzeon-Jye ChiouDivision of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, TaiwanView further author information
,
Te-Kau ChangDepartment of Pediatrics, Taichung Veterans General Hospital, Taichung, TaiwanView further author information
,
Yeu-Chin ChenDivision of Hematology/Oncology, Tri-Service General Hospital, Taipei, TaiwanView further author information
,
Sheng-Fung LinDivision of Hematology/Oncology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanView further author information
,
Cheng-Shyong ChangDepartment of Internal Medicine, Changhua Christian Hospital, Changhua, TaiwanView further author information
,
Yin-Che LuDepartment of Internal Medicine, Chia-Yi Christian Hospital, Chiayi, TaiwanView further author information
,
Su-Peng YehDepartment of Medicine, China Medical University Hospital, Taichung, TaiwanView further author information
,
Tsai-Yun ChenDepartment of Internal Medicine, National Cheng Kung University Hospital, Tainan, TaiwanView further author information
&
Wei-Shou HwangDepartment of Internal Medicine, Chung Shan Medical University Hospital, Taichung, TaiwanView further author information
 show all
Pages 247-254 | Published online: 17 Dec 2018

References

  • Kohgo Y, Urabe A, Kilinç Y et al. Deferasirox decreases liver iron concentration in iron-overloaded patients with myelodysplastic syndromes, aplastic anemia and other rare anemias. Acta Haematol. 2015;134:233–242. doi: 10.1159/000381893
  • Kurtin SE. Myelodysplastic syndromes: diagnosis, treatment planning, and clinical management. Oncology (Williston Park). 2007;21:41–48.
  • Lipton JM, Atsidaftos E, Zyskind I, et al. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer. 2006;6:558–564. doi: 10.1002/pbc.20642
  • Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43–70. doi: 10.1111/j.1365-2141.2009.07842.x
  • Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567–573. doi: 10.1056/NEJM199409013310902
  • Deftereos S, Lambrinoudakis C, Andriopoulos P, et al. A Java-based electronic healthcare record software for beta-thalassaemia. J Med Internet Res. 2001;3:E33.
  • Ko BS, Chang CS, Chang MC, et al. Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement. Int J Hematol. 2014;100:7–15. doi: 10.1007/s12185-014-1607-x
  • Cappellini MD, Taher A. Deferasirox (DEFERASIROX®) for the treatment of iron overload. Acta Haematol. 2009;122:165–173. doi: 10.1159/000243801
  • Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597–1602. doi: 10.1016/S0140-6736(03)13309-0
  • Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003;43:565–572. doi: 10.1177/0091270003253350
  • Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica. 2006;91:1343–1351.
  • Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107:3455–3462. doi: 10.1182/blood-2005-08-3430
  • Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501–508. doi: 10.1111/j.1365-2141.2006.06455.x
  • Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-year prospective study. Eur J Haematol. 2008;80:168–176.
  • Cappellini MD, Elalfy MS, Kattamis A, et al. Efficacy and safety of once-daily, oral iron chelator deferasirox (DEFERASIROX®) in a large group of regularly transfused patients with β-thalassemia major (abstract). Blood. 2008;112:3878. doi: 10.1182/blood-2008-02-138339
  • Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (DEFERASIROX®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873–880.
  • Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82:458–465. doi: 10.1111/j.1600-0609.2009.01228.x
  • Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res. 2010;34:1143–1150. doi: 10.1016/j.leukres.2010.03.009
  • Chang HH, Lu MY, Peng SS, et al. The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan. Ann Hematol. 2015;94:1945–1952. doi: 10.1007/s00277-015-2476-y
  • Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95:557–566. doi: 10.3324/haematol.2009.014696
  • Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;97:1364–1371. doi: 10.3324/haematol.2011.048546

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.